MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

Search

Biogen Inc

Geschlossen

BrancheGesundheitswesen

144.79 -1.19

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

144.47

Max

147.53

Schlüsselkennzahlen

By Trading Economics

Einkommen

394M

635M

Verkäufe

215M

2.6B

KGV

Branchendurchschnitt

14.728

37.257

Gewinnspanne

23.995

Angestellte

7,605

EBITDA

457M

1B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+15.61% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

29. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

3.6B

23B

Vorheriger Eröffnungskurs

145.98

Vorheriger Schlusskurs

144.79

Nachrichtenstimmung

By Acuity

36%

64%

102 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Biogen Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Okt. 2025, 21:50 UTC

Akquisitionen, Fusionen, Übernahmen

Caterpillar to Acquire Australia's RPM Global for $730 Million

10. Okt. 2025, 21:38 UTC

Akquisitionen, Fusionen, Übernahmen

Strathcona Resources Terminates Take-Over Bid for MEG Energy

12. Okt. 2025, 23:47 UTC

Market Talk

Gold Rises, Buoyed by Monetary Debasement Fears -- Market Talk

12. Okt. 2025, 23:39 UTC

Market Talk

Oil Rises on Likely Technical Recovery, Mildly Positive Sentiment -- Market Talk

12. Okt. 2025, 23:22 UTC

Market Talk

New Zealand Braces For Renewed Trade War Uncertainty -- Market Talk

12. Okt. 2025, 23:16 UTC

Akquisitionen, Fusionen, Übernahmen

Caterpillar Inc. Enters Into Agreement To Acquire RPMGlobal >CAT RUL.AU

12. Okt. 2025, 22:32 UTC

Market Talk

Copper, U.S. Thermal Coal Stand Out as Metals Ride Macro Tailwinds -- Market Talk

12. Okt. 2025, 21:28 UTC

Akquisitionen, Fusionen, Übernahmen

RPM Global Says Board Unanimously Recommends Shareholders Accept Caterpillar Offer

12. Okt. 2025, 21:28 UTC

Akquisitionen, Fusionen, Übernahmen

RPM Global Agrees to Takeover by Caterpillar

12. Okt. 2025, 21:28 UTC

Akquisitionen, Fusionen, Übernahmen

RPM Global Says Caterpillar Offering A$5.00/Share in Cash

11. Okt. 2025, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

11. Okt. 2025, 00:18 UTC

Akquisitionen, Fusionen, Übernahmen

Why Biotech May Be Back -- Barrons.com

10. Okt. 2025, 21:07 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Dell Is Just Beginning to Tell Its AI Story. Buy the Stock. -- Barrons.com

10. Okt. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

10. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10. Okt. 2025, 20:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

10. Okt. 2025, 20:06 UTC

Market Talk

Fed Won't Publish Monthly Industrial Data Next Week -- Market Talk

10. Okt. 2025, 20:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10. Okt. 2025, 19:56 UTC

Market Talk

U.S.-China Tension Weighs Down on Treasury Yields, Dollar -- Market Talk

10. Okt. 2025, 19:20 UTC

Market Talk

Oil Futures Sink As Trump Rekindles Trade Tensions -- Market Talk

10. Okt. 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Loss -- Market Talk

10. Okt. 2025, 18:58 UTC

Market Talk

Canada's Jobs Gain Marks a 'Head Fake' For Economy -- Market Talk

10. Okt. 2025, 18:52 UTC

Market Talk

PepsiCo Lays Groundwork for Improvement -- Market Talk

10. Okt. 2025, 18:47 UTC

Market Talk

Precious Metals Turn Higher After Profit-Taking Slide -- Market Talk

10. Okt. 2025, 18:35 UTC

Market Talk

Canada's Next Rate Cut May be Pushed to December -- Market Talk

10. Okt. 2025, 18:31 UTC

Market Talk

Canada's Labor Market Firming. But Conditions Vary Across Country -- Market Talk

10. Okt. 2025, 17:32 UTC

Market Talk

U.S. Oil Rig Count Declines by Four to 418 -- Market Talk

10. Okt. 2025, 16:55 UTC

Ergebnisse

These Stocks Are Moving the Most Today: MP Materials, Nvidia, Alibaba, Venture Global, Applied Digital, Qualcomm, and More -- Barrons.com

10. Okt. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

10. Okt. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Biogen Inc Prognose

Kursziel

By TipRanks

15.61% Vorteil

12-Monats-Prognose

Durchschnitt 169.45 USD  15.61%

Hoch 224 USD

Tief 118 USD

Basierend auf 26 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Biogen Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

26 ratings

12

Buy

14

Halten

0

Sell

Technischer Score

By Trading Central

118.15 / 121.17Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

102 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat